These approvals were based on robust data which showed Trelegy Ellipta improved lung function and symptom control in adult asthma patients.” Regulators have started reviews of GSK's depemokimab ...

Meanwhile in respiratory medicine, the new Ultibro Breezhaler is looking to compete in COPD, but will face stiff competition from GSK's established Seretide, as well as its new Breo Ellipta.

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma ... It launched Trelegy Ellipta, the countrys first single inhaler triple therapy (SITT) for ...

Now, GSK is ready to play catch-up after nabbing its own FDA approval. The FDA approved the British drugmaker's Penmenvy vaccine to protect people ages 10 to 25 against meningococcal serogroups A ...

Feb 14 (Reuters) - Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK (GSK.L), opens new tab, the Financial Times reported on Friday. Citadel has ...

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in. The content of this article is provided for information ...

Teva Pharmaceutical Industries Ltd. ADR-2.29% $19.01B ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.